ArticleJournal of thoracic disease2025
The global, regional, and national burden of early, middle, and late-onset esophageal cancer and trends from 1990 to 2021: a systematic analysis of the Global Burden of Disease Study 2021.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Early-onset esophageal cancer in the context of global burden trends.Journal of thoracic disease · 2026Article
- The underestimated global burden and projections of early-onset stomach and early-onset esophageal cancers.Journal of gastrointestinal oncology · 2026Article
- The rising burden of early-onset esophageal cancer: a call to action.Journal of thoracic disease · 2026Article
- Prognostic impact of treatment modalities and examined lymph nodes count on survival in T3-4 esophageal cancer: a retrospective cohort and predictive modeling study from the Surveillance, Epidemiology, and End Results database.Journal of thoracic disease · 2026Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although the overall burden has gradually decreased, our understanding of the differences in disease burden across various age groups remains incomplete and controversial. This study aimed to provide an updated estimate of the esophageal cancer burden, with a focus on temporal trends and age-specific patterns. Methods: We extracted data from the Global Burden of Disease Study (GBD) 2021. Esophageal cancer was grouped into three groups: early-onset (EOEC, 15-49 years), middle-onset (MOEC, 50-69 years), and late-onset esophageal cancer (LOEC, ≥70 years). Age-standardized rates (ASRs) ensured the comparability of age-standardized incidence rate (ASIR), mortality rate (ASMR), and disability-adjusted life-years (DALYs) rate (ASDR). Joinpoint regression identified temporal trends, and average annual percent change (AAPC) with 95% confidence intervals (CIs) was calculated. Furthermore, we conducted frontier, decomposition, cross-country inequality, and risk factor analyses. Bayesian age-period-cohort (BAPC) model was utilized to forecast future epidemiological trajectories from 2022 to 2035. Results: Globally, although the ASIR of EOEC declined from 1.95 per 100,000 in 1990 to 1.08 in 2021 with an AAPC of -1.9 (95% CI: -2.05 to -1.74, P<0.001), joinpoint regression analysis revealed that the ASIR of LOEC increased from 2014 to 2021. At regional levels, the highest ASRs of early, middle, and late-onset esophageal cancer were mainly observed in Sub-Saharan Africa and East Asia. Moreover, higher disease burden was found in lower sociodemographic index (SDI) countries. Smoking was the most important risk factor for esophageal cancer globally. Furthermore, the ASIR of EOEC and LOEC were projected to increase worldwide from 2022 to 2035. Conclusions: Our findings highlighted the need for targeted cancer control strategies that address population-specific needs, particularly with respect to age, gender, and sociodemographic disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.